Benzopyran sulfonamides as KV1.5 potassium channel blockers.
K(V)1.5 blockers have the potential to be atrium-selective agents for treatment of atrial fibrillation. The benzopyrans provide a template for the synthesis of potent and selective K(V)1.5 blockers.
Lloyd
John
J
Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 5400, Princeton, NJ 08543-5400, USA. john.lloyd@bms.com
Atwal
Karnail S
KS
Finlay
Heather J
HJ
Nyman
Michael
M
Huynh
Tram
T
Bhandaru
Rao
R
Kover
Alexander
A
Schmidt
Joan
J
Vaccaro
Wayne
W
Conder
Mary Lee
ML
Jenkins-West
Tonya
T
Levesque
Paul
P
D001281:Atrial Fibrillation / Q000188:drug therapy*; D016275:Atrial Function / Q000187:drug effects* / Q000502:physiology; D001578:Benzopyrans / Q000737:chemistry / Q000494:pharmacology*; D051666:Kv1.5 Potassium Channel / Q000187:drug effects* / Q000378:metabolism; D008956:Models, Chemical; D026902:Potassium Channel Blockers / Q000138:chemical synthesis / Q000494:pharmacology*; D013449:Sulfonamides / Q000737:chemistry / Q000494:pharmacology*
D001578:Benzopyrans; D051666:Kv1.5 Potassium Channel; D026902:Potassium Channel Blockers; D013449:Sulfonamides